NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

色素性視網膜炎(RP)- 市場分析、流行病學、市場預測 2030年

Retinitis Pigmentosa (RP) - Market Insights, Epidemiology, and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 928274
出版日期 按訂單生產 內容資訊 英文 237 Pages
商品交期: 10個工作天內
價格
色素性視網膜炎(RP)- 市場分析、流行病學、市場預測 2030年 Retinitis Pigmentosa (RP) - Market Insights, Epidemiology, and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 237 Pages
簡介

主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的色素性視網膜炎(RP)2017年的患病數為25萬3,420人,同年的市場規模估算為2億3,723萬美元。

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的色素性視網膜炎(RP)市場調查,疾病概要和現行的治療方法,已上市治療藥及新藥的簡介,主要7個國家的市場趨勢,流行病學的預測,市場規模,患病數的變化與預測,未滿足需求,市場成長要素及障礙等資訊彙整。

目錄

第1章 主要洞察

第2章 色素性視網膜炎(RP)概要

第3章 市場概要

  • 市場佔有率(成果值)
  • 市場佔有率(預測值)

第4章 色素性視網膜炎(RP):疾病的背景和概要

  • 簡介
  • 歷史
  • 關於視網膜
  • 症狀
  • 原因
  • 臨床性特徵
  • 分類
  • 病理生理學
  • 病因
  • 遺傳學
  • 診斷

第5章 病例報告

第6章 主要7個國家的流行病學和患者人口

  • 主要調查結果
  • 調查手法
  • 總診斷患病數
  • 診斷患病數:性別
  • 診斷患病數:各類型
  • 診斷患病數:各子類型
  • 非症候性色素性視網膜炎的診斷患病數:各子類型

第7章 美國的流行病學

  • 假設和根據
  • 總診斷患病數
  • 診斷患病數:性別
  • 診斷患病數:各類型
  • 診斷患病數:各子類型
  • 非症候性色素性視網膜炎的診斷患病數:各子類型

第8章 歐洲5個國家的流行病學

  • 德國
    • 假設和根據
    • 總診斷患病數
    • 診斷患病數:性別
    • 診斷患病數:各類型
    • 診斷患病數:各子類型
    • 非症候性色素性視網膜炎的診斷患病數:各子類型
  • 法國
  • 義大利
  • 西班牙
  • 英國

第9章 日本的流行病學

  • 假設和根據
  • 總診斷患病數
  • 診斷患病數:性別
  • 診斷患病數:各類型
  • 診斷患病數:各子類型
  • 非症候性色素性視網膜炎的診斷患病數:各子類型

第10章 治療流程、現行治療

  • 一般推薦事項
  • 目前治療方法
  • 未來的治療方法

第11章 色素性視網膜炎(RP)的指南方案

第12章 未滿足需求

第13章 已上市治療藥

  • Luxturna:Spark Therapeutics/Novartis
    • 醫藥品概要
    • 法規的里程碑
    • 產品的開發活動
    • 優點與缺點
    • 安全性和有效性
    • 產品簡介

第14章 新藥

  • Key Cross Competition
  • HORA-RPE65:Horama
  • HORA-PDE6B:Horama
  • AAV8-RPGR/BIIB112:Nightstar Therapeutics/Biogen
  • jCell:jCyte
  • Renexus:Neurotech
  • Cenegermin:Dompe Farmaceutici
  • hRPC Cells:ReNeuron
  • UshStat:Sanofi
  • AGN-151597:Allergan
  • AAV-RPGR:MeiraGTx
  • AAV-RPE65:MeiraGTx

第15章 市場分析色素性視網膜炎(RP):主要7個國家

  • 主要調查結果
  • 市場預測調查手法
  • 屬性分析
  • 主要7個國家的市場規模
  • 主要7個國家的市場規模:各治療藥物
  • 新興市場競爭情形

第16章 美國的市場預測

  • 美國的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物

第17章 歐洲5個國家的市場預測

  • 德國的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物
  • 法國的市場規模
  • 義大利的市場規模
  • 西班牙的市場規模
  • 英國的市場規模

第18章 日本的市場預測

  • 日本的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物

第19章 獲取與償付制度

第20章 市場成長要素

第21章 市場障礙

第22章 SWOT分析

第23章 附錄

  • 報告調查手法

第24章 DelveInsight的服務內容

第25章 免責聲明

第26章 關於DelveInsight

目錄
Product Code: DIMI0465

DelveInsight's 'Retinitis Pigmentosa (RP)-Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Retinitis Pigmentosa (RP) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Retinitis Pigmentosa (RP)-Disease Understanding and Treatment Algorithm

Retinitis Pigmentosa (RP)-Overview

Retinitis Pigmentosa (RP) refers to a group of inherited retinal disorders causing retinal degeneration and blindness. RP is characterized by progressive bilateral degeneration of the rod and cone photoreceptors that leads to night blindness and progressive visual field defects. Individuals with RP lose their vision because of the gradual degeneration of photoreceptor (light-sensing) cells of the retina. In most forms of RP (rod-cone dystrophy), night blindness is one of the earliest and most frequent symptoms. Based on clinical impact, RP is classified into three categories that include, non-syndromic, or "simple" (not affecting other organs or tissues), Syndromic (affecting other neurosensory systems such as hearing), and Systemic (affecting multiple tissues. Non-syndromic RP has three-stage: early stage, mid and end-stage. Non-syndromic RP is further subcategorized as autosomal dominant RP, autosomal recessive RP, X-linked RP, sporadic/simplex RP, and Leber congenital amaurosis (LCA).

Syndromic and Systemic RP are subcategorized into usher syndrome, bardet-biedl syndrome, and others.

Retinitis Pigmentosa (RP) Diagnosis

The diagnosis of RP is suspected in patients with poor night vision or family history (more than 40% of RP cases in the US have no family history). It relies upon documentation of rod dysfunction as measured by dark adaptation or electroretinogram, progressive loss in photoreceptor function, loss of peripheral vision and bilateral involvement.

The most common findings on ocular examination are usually preserved visual acuity until late-stage disease and reduced visual fields. Most adult patients have posterior subcapsular cataracts and visual acuity that varies from 20/20 to near blindness late in the disease.

Retinitis Pigmentosa (RP) Treatment

It covers the details of conventional and current medical therapies available in the Retinitis Pigmentosa (RP) market for the treatment of the condition. It also provides the treatment guidelines and algorithms of the 7MM.

The DelveInsight's Retinitis Pigmentosa (RP) market report gives a thorough understanding of Retinitis Pigmentosa (RP) by including details such as disease definition, causes, risk factors, pathogenesis, and diagnosis.

Retinitis Pigmentosa (RP) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent Cases of Retinitis Pigmentosa in the 7MM, Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM, Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM, Subtype-Specific Diagnosed Prevalence of Syndromic and Systemic RP in the 7MM, and Subtype-specific Diagnosed Prevalent Cases of Non-Syndromic RP in the 7MM) scenario of Retinitis Pigmentosa in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017-2030.

Key Findings

This section provides glimpses of the Retinitis Pigmentosa epidemiology in the 7MM market.

According to DelveInsight's, the total diagnosed prevalent population of Retinitis Pigmentosa (RP) in the 7MM was 253,420 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

Country Wise-Retinitis Pigmentosa Epidemiology

The epidemiology segment also provides the Retinitis Pigmentosa epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Retinitis Pigmentosa Drug Chapters

The drug chapter segment of the Retinitis Pigmentosa report encloses the detailed analysis of Retinitis Pigmentosa marketed drugs and late stage (phase III) pipeline drugs. It also helps to understand the RP clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Retinitis Pigmentosa Marketed Drugs

Luxturna: Spark Therapeutics/ Novartis

Luxturna (AAV2-hRPE65v2; voretigene neparvovec), known as voretigene neparvovec-rzyl, is a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65 gene. It provides a copy of the RPE65 gene to act in place of the mutated RPE65 gene. This working gene can restore vision and improve sight. The drug is administered as a subretinal single injection below the retina in patients who have confirmed RPE65 mutations and viable retinal cells.

The drug was developed and commercialized in the US by Spark Therapeutics. In Europe, Novartis is currently marketing Luxturna as per a licensing agreement covering the development, registration and commercialization rights of Luxturna in markets outside the US. It is indicated for the treatment of patients with vision loss due to Leber's congenital amaurosis or retinitis pigmentosa inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations.

Products detail in the report…

Retinitis Pigmentosa Emerging Drugs

HORA-RPE65: Horama

Horama is developing a HORA-RPE65 gene replacement product for the treatment of RPE65 Retinitis Pigmentosa. It is an AAV 2/4 encapsidating the human RPE65 gene under the control of the human native RPE65 promoter. The company investigational candidate HORA-RPE65 provides the cell with a non-mutated copy of the human RPE65 gene, which can express functional RPE65 protein to halt or at least significantly delay retinal degeneration in patients with inherited retinal dystrophies caused by RPE65 gene mutations.

The drug is being delivered in the form of a sterile vector suspension injected directly into the subretinal space, where it induces transgene expression in retinal pigment epithelium cells. Horama had already completed a single-center, open, non-randomized phase I/II clinical trial which accessed the safety and effectiveness of HORA-RPE65 in patients with retinal dystrophy caused by RPE65 gene abnormalities.

Products detail in the report…

Retinitis Pigmentosa Market Outlook

The Retinitis Pigmentosa market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Retinitis Pigmentosa market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of Retinitis Pigmentosa market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Retinitis Pigmentosa 7MM market is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Retinitis Pigmentosa 7MM market. The market size of Retinitis Pigmentosa in the 7MM market was USD 237.27 million in 2017.

The United States Market Outlook

This section provides the total Retinitis Pigmentosa market size and market size by therapies in the United States.

Among the 7MM countries, the United States had the highest market size of RP in 2017, which accounts for 56.40% of the total market. At present, the growth of market size for RP is attributed to support treatment regimens, the only approved therapy (Luxturna), as well as, emerging therapies. The market size for RP was found to be USD 133.82 million in 2017.

EU-5 Market Outlook

The total Retinitis Pigmentosa market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Germany accounts for 26.28% of the total EU-5 market of RP. DelveInsight's estimates suggest that the overall market size of RP was observed to remain nearly constant from USD 20.90 million in 2017 to USD 21.33 million in 2018. This is attributed to the dependency of the market size of RP on supportive treatment regimens, at present. However, with the recent approval of Luxturna, the market size of RP is expected to experience a significant increase. The dearth of marketed treatment regimens for RP is the foremost unmet need of this therapeutic area, which is primarily responsible for nearly constant market size.

Japan Market Outlook

The total Retinitis Pigmentosa market size and market size by therapies in Japan are provided.

Retinitis Pigmentosa Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Retinitis Pigmentosa market or expected to get launched in the market during the study period 2017-2030. The analysis covers Retinitis Pigmentosa market uptake by drugs; patient uptake by therapies; and sales of each drug.

Retinitis Pigmentosa Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Retinitis Pigmentosa emerging therapies.

Reimbursement Scenario in Retinitis Pigmentosa

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Retinitis Pigmentosa domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Retinitis Pigmentosa market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Retinitis Pigmentosa market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Retinitis Pigmentosa, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Retinitis Pigmentosa epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Retinitis Pigmentosa are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Retinitis Pigmentosa market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Retinitis Pigmentosa market

Report Highlights

  • In the coming years, Retinitis Pigmentosa market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Retinitis Pigmentosa R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Retinitis Pigmentosa. Launch of emerging therapies will significantly impact the Retinitis Pigmentosa market
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Retinitis Pigmentosa Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Retinitis Pigmentosa Pipeline Analysis
  • Retinitis Pigmentosa Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Retinitis Pigmentosa Report Key Strengths

  • Eleven Years Forecast
  • 7MM Coverage
  • Retinitis Pigmentosa Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Retinitis Pigmentosa Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Retinitis Pigmentosa market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Retinitis Pigmentosa total market size as well as market size by therapies across the globe during the forecast period (2020-2030)?
  • What are the key findings pertaining to the market across the globe and which country will have the largest Retinitis Pigmentosa market size during the forecast period (2020-2030)?
  • At what CAGR, the Retinitis Pigmentosa market is expected to grow at the 7MM level during the forecast period (2020-2030)?
  • What would be the Retinitis Pigmentosa market outlook across the globe during the forecast period (2020-2030)?
  • What would be the Retinitis Pigmentosa market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Retinitis Pigmentosa?
  • What is the historical Retinitis Pigmentosa patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Retinitis Pigmentosa at the 7MM level?
  • What will be the growth opportunities across the globe with respect to the patient population pertaining to Retinitis Pigmentosa?
  • Out of the above-mentioned countries, which country would have the highest Incident population of Retinitis Pigmentosa during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the globe during the forecast period (2020-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Retinitis Pigmentosa along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Retinitis Pigmentosa in the 7MM?
  • What are the Retinitis Pigmentosa marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Retinitis Pigmentosa?
  • How many therapies are developed by each company for the treatment of Retinitis Pigmentosa?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Retinitis Pigmentosa?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Retinitis Pigmentosa therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Retinitis Pigmentosa and their status?
  • What are the key designations that have been granted for the emerging therapies for Retinitis Pigmentosa?
  • What are the 7MM historical and forecasted market of Retinitis Pigmentosa?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Retinitis Pigmentosa.
  • To understand the future market competition in the Retinitis Pigmentosa market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Retinitis Pigmentosa in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Retinitis Pigmentosa market.
  • To understand the future market competition in the Retinitis Pigmentosa market.

Table of Contents

1. Key Insights

2. Executive Summary of Retinitis Pigmentosa (RP)

3. Retinitis Pigmentosa (RP): Market Overview at a Glance

  • 3.1. Total Market Share (%) Distribution of RP in 2017
  • 3.2. Total Market Share (%) Distribution of RP in 2030

4. Retinitis Pigmentosa: Disease Background and Overview

  • 4.1. Introduction
  • 4.2. History
  • 4.3. Facts about Retina
  • 4.4. Signs and Symptoms
  • 4.5. Causes of Retinitis Pigmentosa
  • 4.6. Clinical Features
  • 4.7. Classification of Retinitis Pigmentosa
    • 4.7.1. Classification as per Japanese guidelines
  • 4.8. Pathophysiology
  • 4.9. Etiology
  • 4.10. Genetics of Retinitis Pigmentosa
    • 4.10.1. Types of non-syndromic RP inheritance
  • 4.11. Diagnosis
    • 4.11.1. Recommended Diagnostic Tests
    • 4.11.2. Differential diagnosis of RP

5. Case Reports

  • 5.1. A Case of Unilateral Retinitis Pigmentosa Associated with Full-Thickness Macular Hole
  • 5.2. Eleven-Year Follow-Up of a Japanese Retinitis Pigmentosa Patient with an HK1 Gene Mutation
  • 5.3. Unilateral Retinitis Pigmentosa: Visual field changes in a 31-year-old female

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. Epidemiology Methodology
  • 6.3. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the 7MM
  • 6.4. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM
  • 6.5. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM
  • 6.6. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic Retinitis Pigmentosa in the 7MM
  • 6.7. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic Retinitis Pigmentosa in the 7MM

7. United States Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the United States
  • 7.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United States
  • 7.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United States
  • 7.5. Sub-Type Specific Diagnosed Prevalence of Syndromic and Systemic RP in the United States
  • 7.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the United States

8. EU5 Epidemiology

  • 8.1. Germany Epidemiology
    • 8.1.1. Assumptions and Rationale
    • 8.1.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Germany
    • 8.1.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany
    • 8.1.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany
    • 8.1.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Germany
    • 8.1.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Germany
  • 8.2. France Epidemiology
    • 8.2.1. Assumptions and rationale
    • 8.2.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in France
    • 8.2.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France
    • 8.2.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France
    • 8.2.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in France
    • 8.2.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in France
  • 8.3. Italy Epidemiology
    • 8.3.1. Assumptions and Rationale
    • 8.3.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Italy
    • 8.3.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy
    • 8.3.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy
    • 8.3.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Italy
    • 8.3.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Italy
  • 8.4. Spain Epidemiology
    • 8.4.1. Assumptions and Rationale
    • 8.4.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Spain
    • 8.4.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain
    • 8.4.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain
    • 8.4.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Spain
    • 8.4.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Spain
  • 8.5. United Kingdom Epidemiology
    • 8.5.1. Assumptions and Rationale
    • 8.5.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the United Kingdom
    • 8.5.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United Kingdom
    • 8.5.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United Kingdom
    • 8.5.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the United Kingdom
    • 8.5.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the United Kingdom

9. Japan Epidemiology

  • 9.1. Assumptions and Rationale
  • 9.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Japan
  • 9.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan
  • 9.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan
  • 9.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Japan
  • 9.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Japan

10. Treatment Algorithm, Current Treatment, and Medical Practices

  • 10.1. General recommendations for RP treatment
  • 10.2. Current Treatment Modalities
  • 10.3. Future Treatment modalities

11. Proposed Guidelines for Retinitis Pigmentosa

12. Unmet Needs

13. Marketed Products

  • 13.1. Luxturna: Spark Therapeutics/ Novartis
    • 13.1.1. Drug Description
    • 13.1.2. Regulatory Milestones
    • 13.1.3. Product Development Activities
    • 13.1.4. Advantages and Disadvantages
    • 13.1.5. Safety and Efficacy
    • 13.1.6. Product Profile

14. Emerging Therapies

  • 14.1. Key Cross Competition
  • 14.2. HORA-RPE65: Horama
    • 14.2.1. Product Description
    • 14.2.2. Other development Activities
    • 14.2.3. Product Profile
  • 14.3. HORA-PDE6B: Horama
    • 14.3.1. Product Description
    • 14.3.2. Other development Activities
    • 14.3.3. Clinical Development
    • 14.3.4. Product Profile
  • 14.4. AAV8-RPGR/BIIB112: Nightstar Therapeutics/Biogen
    • 14.4.1. Product Description
    • 14.4.2. Other development Activities
    • 14.4.3. Clinical Development
    • 14.4.4. Safety and Efficacy
    • 14.4.5. Product Profile
  • 14.5. jCell: jCyte
    • 14.5.1. Product Description
    • 14.5.2. Other development Activities
    • 14.5.3. Clinical Development
    • 14.5.4. Safety and Efficacy
    • 14.5.5. Product Profile
  • 14.6. Renexus: Neurotech
    • 14.6.1. Product Description
    • 14.6.2. Other Development Activities
    • 14.6.3. Clinical Development
    • 14.6.4. Product Profile
  • 14.7. Cenegermin: Dompe Farmaceutici
    • 14.7.1. Product Description
    • 14.7.2. Other development Activities
    • 14.7.3. Clinical Development
    • 14.7.4. Safety and Efficacy
    • 14.7.5. Product Profile
  • 14.8. hRPC Cells : ReNeuron
    • 14.8.1. Product Description
    • 14.8.2. Other development Activities
    • 14.8.3. Clinical Development
    • 14.8.4. Safety and Efficacy
    • 14.8.5. Product Profile
  • 14.9. UshStat: Sanofi (Terminated)
    • 14.9.1. Product Description
    • 14.9.2. Other development Activities
    • 14.9.3. Clinical Development
    • 14.9.4. Safety and Efficacy
    • 14.9.5. Product Profile
  • 14.10. AGN-151597: Allergan
    • 14.10.1. Product Description
    • 14.10.2. Other development Activities
    • 14.10.3. Clinical Development
    • 14.10.4. Product Profile
  • 14.11. AAV-RPGR: MeiraGTx
    • 14.11.1. Product Description
    • 14.11.2. Other development Activities
    • 14.11.3. Clinical Development
    • 14.11.4. Product Profile
  • 14.12. AAV-RPE65: MeiraGTx
    • 14.12.1. Product Description
    • 14.12.2. Other development Activities
    • 14.12.3. Clinical Development
    • 14.12.4. Safety and Efficacy
    • 14.12.5. Product Profile

15. Retinitis Pigmentosa (RP): 7MM Market Analysis

  • 15.1. Key Findings
  • 15.2. Market Estimation Methodology
  • 15.3. Attribute Analysis
  • 15.4. Market Size of Retinitis Pigmentosa in the 7MM
  • 15.5. Market Size of Retinitis Pigmentosa by Therapies in the 7MM
  • 15.6. Retinitis Pigmentosa: Emerging Market Competition

16. United States: Market Outlook

  • 16.1. United States Market Size
    • 16.1.1. Total Market size of Retinitis Pigmentosa in the United States
    • 16.1.2. Market Size of Retinitis Pigmentosa by Therapies in the US

17. EU-5 countries: Market Outlook

  • 17.1. Germany Market Size
    • 17.1.1. Total Market size of Retinitis Pigmentosa in Germany
    • 17.1.2. Market Size of Retinitis Pigmentosa by therapies in Germany
  • 17.2. France Market Size
    • 17.2.1. Total Market size of Retinitis Pigmentosa in France
    • 17.2.2. Market Size of Retinitis Pigmentosa by therapies in France
  • 17.3. Italy Market Size
    • 17.3.1. Total Market size of Retinitis Pigmentosa in Italy
    • 17.3.2. Market Size of Retinitis Pigmentosa by therapies in Italy
  • 17.4. Spain Market Size
    • 17.4.1. Total Market size of Retinitis Pigmentosa in Spain
    • 17.4.2. Market Size of Retinitis Pigmentosa by therapies in Spain
  • 17.5. United Kingdom Market Size
    • 17.5.1. Total Market size of Retinitis Pigmentosa in the United Kingdom
    • 17.5.2. Market Size of Retinitis Pigmentosa by therapies in the UK

18. Japan Market Outlook

  • 18.1. Japan Market Size
    • 18.1.1. Total Market size of Retinitis Pigmentosa in Japan
    • 18.1.2. Market Size of Retinitis Pigmentosa by therapies in Japan

19. Access and Reimbursement Overview of Retinitis Pigmentosa

  • 19.1. Current therapy-Luxturna
  • 19.2. Outline of the Patient Journey with Luxturna Introduced by Spark Therapeutics
  • 19.3. Coverage Parameters for Luxturna
  • 19.4. Payer billing guidelines for claims processing and prompt payment of Luxturna
  • 19.5. Future Potential Therapies

20. Market Drivers

21. Market Barriers

22. SWOT Analysis

23. Appendix

  • 23.1. Report Methodology

24. DelveInsight Capabilities

25. Disclaimer

26. About DelveInsight

List of Tables

  • Table 1 Summary of Retinitis Pigmentosa (RP) Market, Epidemiology, and Key Events (2017-2030)
  • Table 2 Summary of Genes Implicated in RP
  • Table 3 Syndromic retinitis pigmentosa
  • Table 4 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the 7MM (2017-2030)
  • Table 5 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM (2017-2030)
  • Table 6 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM (2017-2030)
  • Table 7 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the 7MM (2017-2030)
  • Table 8 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the 7MM (2017-2030)
  • Table 9 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the US (2017-2030)
  • Table 10 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the US (2017-2030)
  • Table 11 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United States (2017-2030)
  • Table 12 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the US (2017-2030)
  • Table 13 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the US (2017-2030)
  • Table 14 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Germany (2017-2030)
  • Table 15 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany (2017-2030)
  • Table 16 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany (2017-2030)
  • Table 17 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Germany (2017-2030)
  • Table 18 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Germany (2017-2030)
  • Table 19 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in France (2017-2030)
  • Table 20 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France (2017-2030)
  • Table 21 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France (2017-2030)
  • Table 22 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in France (2017-2030)
  • Table 23 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in France (2017-2030)
  • Table 24 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Italy (2017-2030)
  • Table 25 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy (2017-2030)
  • Table 26 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy (2017-2030)
  • Table 27 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Italy (2017-2030)
  • Table 28 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Italy (2017-2030)
  • Table 29 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Spain (2017-2030)
  • Table 30 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain (2017-2030)
  • Table 31 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain (2017-2030)
  • Table 32 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Spain (2017-2030)
  • Table 33 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Spain (2017-2030)
  • Table 34 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the UK (2017-2030)
  • Table 35 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the UK (2017-2030)
  • Table 36 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the UK (2017-2030)
  • Table 37 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the UK (2017-2030)
  • Table 38 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the UK (2017-2030)
  • Table 39 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Japan (2017-2030)
  • Table 40 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan (2017-2030)
  • Table 41 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan (2017-2030)
  • Table 42 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Japan (2017-2030)
  • Table 43 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Japan (2017-2030)
  • Table 44 Associated conditions and corresponding treatment plans for RP Patients
  • Table 45 Key Cross of Emerging Drugs
  • Table 46 Key Cross of Emerging Drugs (Contd.)
  • Table 47 AAV8-RPGR, Clinical Trial Description, 2020
  • Table 48 AAV8-RPGR, Clinical Trial Description, 2020
  • Table 49 jCell, Clinical Trial Description, 2020
  • Table 50 Renexus (NT-501), Clinical Trial Description, 2020
  • Table 51 Cenegermin (rhNGF), Clinical Trial Description, 2020
  • Table 52 hRPC, Clinical Trial Description, 2020
  • Table 53 UshStat, Clinical Trial Description, 2020
  • Table 54 RST-001, Clinical Trial Description, 2020
  • Table 55 AAV-RPGR, Clinical Trial Description, 2020
  • Table 56 AAV RPE65, Clinical Trial Description, 2020
  • Table 57 Market Size of Retinitis Pigmentosa in 7MM in USD Million (2017-2030)
  • Table 58 Market Size of Retinitis Pigmentosa by therapies in the 7MM, in USD Million (2017-2030)
  • Table 59 The US Market Size of Retinitis Pigmentosa in USD Million (2017-2030)
  • Table 60 Market Size of Retinitis Pigmentosa by therapies in the US, in USD Million (2017-2030)
  • Table 61 Expected Launch Date of Emerging Drugs in EU-5 countries
  • Table 62 Germany Market Size of Retinitis Pigmentosa in USD Million (2017-2030)
  • Table 63 Market Size of Retinitis Pigmentosa by therapies in Germany, in USD Million (2017-2030)
  • Table 64 France Market Size of Retinitis Pigmentosa in USD Million (2017-2030)
  • Table 65 Market Size of Retinitis Pigmentosa by therapies in France, in USD Million (2017-2030)
  • Table 66 Italy Market Size of Retinitis Pigmentosa in USD Million (2017-2030)
  • Table 67 Market Size of Retinitis Pigmentosa by therapies in Italy, in USD Million (2017-2030)
  • Table 68 Spain Market Size of Retinitis Pigmentosa in USD Million (2017-2030)
  • Table 69 Market Size of Retinitis Pigmentosa by therapies in Spain, in USD Million (2017-2030)
  • Table 70 The UK Market Size of Retinitis Pigmentosa in USD Million (2017-2030)
  • Table 71 Market Size of Retinitis Pigmentosa by therapies in the UK, in USD Million (2017-2030)
  • Table 72 Expected Launch Date of Emerging Drugs in Japan
  • Table 73 Japan Market Size of Retinitis Pigmentosa in USD Million (2017-2030)
  • Table 74 Market Size of Retinitis Pigmentosa by therapies in Japan, in USD Million (2017-2030)

List of Figures

  • Figure 1 Structure of Retina
  • Figure 2 Normal Eye Anatomy Versus Eye Anatomy in Retinitis Pigmentosa
  • Figure 3 Typical Symptoms associated with RP
  • Figure 4 Typical Symptoms associated with RP
  • Figure 5 Classification of RP
  • Figure 6 Specific clinical diagnosis of RP
  • Figure 7 Pathophysiology of RP
  • Figure 8 Altered Retinoid Cycle Metabolic Pathway
  • Figure 9 Types of non-syndromic based on the inheritance pattern
  • Figure 10 Pattern of autosomal dominant RP inheritance
  • Figure 11 Pattern of autosomal recessive RP inheritance.
  • Figure 12 Pattern of X-linked RP inheritance
  • Figure 13 Altered Retinoid Cycle Metabolic Pathway
  • Figure 14 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the 7MM (2017-2030)
  • Figure 15 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM (2017-2030)
  • Figure 16 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM (2017-2030)
  • Figure 17 Sub-Type Specific Diagnosed Prevalence of syndromic & Systemic RP in the 7MM (2017-2030)
  • Figure 18 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the 7MM (2017-2030)
  • Figure 19 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the US (2017-2030)
  • Figure 20 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the US (2017-2030)
  • Figure 21 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United States (2017-2030)
  • Figure 22 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the US (2017-2030)
  • Figure 23 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the US (2017-2030)
  • Figure 24 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Germany (2017-2030)
  • Figure 25 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany (2017-2030)
  • Figure 26 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany (2017-2030)
  • Figure 27 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Germany (2017-2030)
  • Figure 28 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Germany (2017-2030)
  • Figure 29 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in France (2017-2030)
  • Figure 30 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France (2017-2030)
  • Figure 31 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France (2017-2030)
  • Figure 32 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in France (2017-2030)
  • Figure 33 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in France (2017-2030)
  • Figure 34 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Italy (2017-2030)
  • Figure 35 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy (2017-2030)
  • Figure 36 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy (2017-2030)
  • Figure 37 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Italy (2017-2030)
  • Figure 38 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Italy (2017-2030)
  • Figure 39 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Spain (2017-2030)
  • Figure 40 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain (2017-2030)
  • Figure 41 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain (2017-2030)
  • Figure 42 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Spain (2017-2030)
  • Figure 43 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Spain (2017-2030)
  • Figure 44 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the UK (2017-2030)
  • Figure 45 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the UK (2017-2030)
  • Figure 46 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the UK (2017-2030)
  • Figure 47 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the UK (2017-2030)
  • Figure 48 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the UK (2017-2030)
  • Figure 49 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Japan (2017-2030)
  • Figure 50 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan (2017-2030)
  • Figure 51 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa RP in Japan (2017-2030)
  • Figure 52 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Japan (2017-2030)
  • Figure 53 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Japan (2017-2030)
  • Figure 54 Future Treatment Modalities for Retinitis Pigmentosa
  • Figure 55 Unmet Needs of Retinitis Pigmentosa
  • Figure 56 Market Size of Retinitis Pigmentosa in the 7MM in USD Million (2017-2030)
  • Figure 57 Market Size of Retinitis Pigmentosa by therapies in the 7MM, in USD Million (2017-2030)
  • Figure 58 Market Size of Retinitis Pigmentosa in the US, USD Millions (2017-2030)
  • Figure 59 Market Size of Retinitis Pigmentosa by therapies in the US, in USD Million (2017-2030)
  • Figure 60 Market Size of Retinitis Pigmentosa in Germany, USD Millions (2017-2030)
  • Figure 61 Market Size of Retinitis Pigmentosa by therapies in Germany, in USD Million (2017-2030)
  • Figure 62 Market Size of Retinitis Pigmentosa in France, USD Millions (2017-2030)
  • Figure 63 Market Size of Retinitis Pigmentosa by therapies in France, in USD Million (2017-2030)
  • Figure 64 Market Size of Retinitis Pigmentosa in Italy, USD Millions (2017-2030)
  • Figure 65 Market Size of Retinitis Pigmentosa by therapies in Italy in USD Million (2017-2030)
  • Figure 66 Market Size of Retinitis Pigmentosa in Spain, USD Millions (2017-2030)
  • Figure 67 Market Size of Retinitis Pigmentosa by therapies in Spain in USD Million (2017-2030)
  • Figure 68 Market Size of Retinitis Pigmentosa in the UK, USD Millions (2017-2030)
  • Figure 69 Market Size of Retinitis Pigmentosa by therapies in the UK in USD Million (2017-2030)
  • Figure 70 Market Size of Retinitis Pigmentosa in Japan, USD Millions (2017-2030)
  • Figure 71 Market Size of Retinitis Pigmentosa by therapies in Japan in USD Million (2017-2030)
  • Figure 72 Diagnosis Coding
  • Figure 73 HCPCS Codes
  • Figure 74 Modifiers
  • Figure 75 C code
  • Figure 76 J code
  • Figure 77 J code
  • Figure 78 Market Drivers
  • Figure 79 Market Barriers
  • Figure 80 SWOT Analysis